AUY922 in Patient With Stage IV NSCLC

Summary

This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC.

Timeline

Start

2014-01

Primary completion

2017-02

Completion

2017-02

Drugs

Indications